Ibio vs Kazia Therapeutics
Ibio is the larger business, with $100,000 of revenue in fiscal 2026 against $27,211 for Kazia Therapeutics (3.7 times as much). Ibio grew faster (-75.0% against -98.2%). Ibio kept more of each dollar of sales as profit: a net margin of -33044.0% against -49290.5%.
| Latest fiscal year | IbioIBIO, 2026 | Kazia TherapeuticsKZIA, 2025 |
|---|---|---|
| Revenue | $100,000 | $27,211 |
| Revenue growth | -75.0% | -98.2% |
| Net income | −$33.0m | −$13.4m |
| Operating margin | -35141.0% | — |
| Net margin | -33044.0% | -49290.5% |
| Return on equity | -65.7% | — |
| Free cash flow | −$23.8m | −$8.6m |
| Cash | $56.4m | $2.9m |
| Total debt | $0 | $260,291 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 23 | — |
| Market value | $45.5m | $8.8m |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | — |
| Insider trades, 12 months | 4 buys, 0 sales | 0 buys, 0 sales |